- Home
- THRD vs BARK Comparison
THRD vs BARK Comparison
Compare THRD & BARK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- BARK
- Stock Information
- Founded
- THRD 2019
- BARK 2011
- Country
- THRD United States
- BARK United States
- Employees
- THRD N/A
- BARK N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- BARK Department/Specialty Retail Stores
- Sector
- THRD Health Care
- BARK Consumer Discretionary
- Exchange
- THRD Nasdaq
- BARK Nasdaq
- Market Cap
- THRD 157.7M
- BARK 342.7M
- IPO Year
- THRD 2022
- BARK N/A
- Fundamental
- Price
- THRD $3.45
- BARK $1.39
- Analyst Decision
- THRD Buy
- BARK Buy
- Analyst Count
- THRD 3
- BARK 2
- Target Price
- THRD $14.00
- BARK $2.50
- AVG Volume (30 Days)
- THRD 435.5K
- BARK 936.7K
- Earning Date
- THRD 03-25-2025
- BARK 02-05-2025
- Dividend Yield
- THRD N/A
- BARK N/A
- EPS Growth
- THRD N/A
- BARK N/A
- EPS
- THRD N/A
- BARK N/A
- Revenue
- THRD N/A
- BARK $490,256,000.00
- Revenue This Year
- THRD N/A
- BARK $3.12
- Revenue Next Year
- THRD N/A
- BARK $7.76
- P/E Ratio
- THRD N/A
- BARK N/A
- Revenue Growth
- THRD N/A
- BARK N/A
- 52 Week Low
- THRD $3.18
- BARK $1.01
- 52 Week High
- THRD $16.94
- BARK $2.56
- Technical
- Relative Strength Index (RSI)
- THRD 30.03
- BARK 27.58
- Support Level
- THRD $3.36
- BARK $1.48
- Resistance Level
- THRD $3.65
- BARK $1.77
- Average True Range (ATR)
- THRD 0.14
- BARK 0.11
- MACD
- THRD 0.16
- BARK -0.03
- Stochastic Oscillator
- THRD 35.48
- BARK 0.98
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About BARK BARK Inc.
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.